Medicare GLP-1 Coverage July 2026: Who Qualifies for $50/Month Wegovy and Zepbound — and Who Got Left Behind

# Medicare GLP-1 Coverage July 2026: Who Qualifies for $50/Month Wegovy and Zepbound — and Who Got Left Behind

> **Quick answer:** Starting July 1, 2026, Medicare will cover Wegovy and Zepbound for eligible Part D beneficiaries at a $50 monthly copay through the Medicare GLP-1 Bridge. To qualify, you need a BMI of 35 or higher, or a BMI of 27 or higher with a qualifying condition like hypertension or heart failure. But the $50 copay does NOT count toward your Part D out-of-pocket cap — and a larger 2027 expansion just collapsed. Meanwhile, 24 million people lost private GLP-1 coverage in the past year, leaving most Americans still facing $1,000+ monthly list prices unless they use manufacturer direct programs.

*This article is for informational purposes only and does not replace professional medical advice. Consult a healthcare provider for medical concerns about GLP-1 medications, Medicare eligibility, or any decisions about starting or stopping prescription medications.*

Medicare GLP-1 coverage arrives July 1, 2026 — the first time in the program's history that obesity drugs have been formally covered. But the same week CMS announced the program's details, it also quietly paused a larger expansion that was supposed to follow. Understanding both moves — and the simultaneous private insurance retreat — is essential for anyone trying to navigate GLP-1 access right now.

## What the Medicare GLP-1 Bridge Actually Covers

The Medicare GLP-1 Bridge is a demonstration program run by the Centers for Medicare and Medicaid Services (CMS). It runs from **July 1, 2026 through December 31, 2027** — an 18-month window that gives Medicare beneficiaries access to anti-obesity medications for the first time.